MedTrace Logo

A New Study Evaluating the Activity of Modular CAR T for mYeloma

NCT04795882 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-11-20

No results posted yet for this study

Summary

This is a Phase 1 rolling 6 trial design evaluating safety of a novel BCMA Chimeric Antigen Receptor (CAR) alone and of CAR T cells engineered to co-express BCMA CAR and a CD19 CAR in patients with relapsed / refractory Multiple Myeloma.

The study will assess the feasibility of generating these Advanced Therapy Investigational Products (ATIMPs) and the safety of administering the CAR T cells (either BCMA alone or co-expressed with CD19) in patients with relapsed / refractory multiple myeloma.

Conditions

Interventions

BIOLOGICAL

BCMA CAR T cells

Infusion with ATIMP: BCMA CAR T-cells

BIOLOGICAL

BCMA/CD19 CAR T cells

Infusion with ATIMP: BCMA/CD19 CAR T-cells

Sponsors & Collaborators

  • University College, London

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-22
Primary Completion
2029-03-31
Completion
2029-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04795882 on ClinicalTrials.gov